# Editas Medicine (EDIT) — Analyst Forecast

EDIT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/edit/forecast

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 8, 2026 | Wells Fargo | Upgraded | Equal-Weight → Overweight | $6.00 |
| Sep 23, 2026 | Guggenheim | Upgraded | Neutral → Buy | $5.00 |
| Aug 18, 2026 | Ladenburg Thalmann | Initiated Coverage | Buy | $6.00 |
| May 5, 2026 | Chardan Capital | Maintained | Buy | $4.00 |
| Mar 10, 2026 | Jones Trading | Upgraded | Hold → Buy | $8.00 |
| Mar 9, 2026 | Chardan Capital | Maintained | Buy | $3.50 |
| Sep 5, 2025 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Sep 3, 2025 | Wells Fargo | Maintained | Equal-Weight | $4.00 |
| Aug 15, 2025 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Aug 13, 2025 | Baird | Maintained | Outperform | $6.00 |
| May 13, 2025 | Baird | Maintained | Outperform | $4.00 |
| Apr 28, 2025 | HC Wainwright & Co. | Initiated Coverage | Buy | $3.00 |
| Dec 16, 2024 | JP Morgan | Downgraded | Neutral → Underweight | — |
| Dec 16, 2024 | Evercore ISI Group | Maintained | Outperform | $5.00 |
| Dec 13, 2024 | Stifel | Downgraded | Buy → Hold | $3.00 |
| Dec 13, 2024 | Baird | Maintained | Outperform | $8.00 |
| Dec 13, 2024 | Chardan Capital | Downgraded | Buy → Neutral | — |
| Dec 13, 2024 | Barclays | Maintained | Equal-Weight | $3.00 |
| Dec 13, 2024 | RBC Capital | Maintained | Sector Perform | $4.00 |
| Dec 11, 2024 | Wells Fargo | Downgraded | Overweight → Equal-Weight | $4.00 |

## Frequently Asked Questions

### What is the latest analyst rating on EDIT?

On Oct 8, 2026, Wells Fargo upgraded Editas Medicine to Overweight with a price target of $6.00.

## Similar Stocks

- [CRSP](https://www.lighthorse.io/tickers/crsp) — CRISPR Therapeutics AG - Common Shares
- [NTLA](https://www.lighthorse.io/tickers/ntla) — Intellia Therapeutics, Inc. - Common Stock
- [BEAM](https://www.lighthorse.io/tickers/beam) — Beam Therapeutics Inc. - Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).